Chikungunya virus

In November 2023, the U.S. Food and Drug Administration approved a chikungunya vaccine, IXCHIQ (manufactured by Valenva) for adults aged 18 years and older. In February 2024, the U.S. Advisory Committee on Immunization Practices (ACIP) approved recommendations for use of the vaccine among certain people who travel abroad and for laboratory workers in the United States. The groups for whom vaccination is recommended and may be considered can be found here. Information on locations with outbreaks and recent transmission can be found here. Additional information will be posted on this website and the CDC’s ACIP vaccine website in future.

Woman Feeling Sick, Having Headache, Painful Body Pain

Chikungunya virus is spread to people by the bite of an infected mosquito. The most common symptoms of infection are fever and joint pain. Other symptoms may include headache, muscle pain, joint swelling, or rash. Outbreaks have occurred in countries in Africa, Americas, Asia, Europe, and the Caribbean, Indian and Pacific Oceans. There is a risk the virus will be spread to unaffected areas by infected travelers. There is currently no medicine to treat chikungunya virus infection. Travelers can protect themselves by preventing mosquito bites. When traveling to countries with chikungunya virus, use insect repellent; wear long-sleeved shirts and pants; and stay in places with air conditioning or that use window and door screens.